(Source: Business Wire)
Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, today
announced its financial results for the third quarter of 2009.
GAAP revenues for the third quarter of 2009 were $53.1 million, a 24%
increase from $43.0 million in the third quarter of 2008. Within total
revenues, electronic data capture (EDC) license, application hosting and
other related revenues were $38.5 million, representing 71% of third
quarter total non-GAAP revenues and an increase of 18% from $32.7
million in the prior year period.
Bob Weiler, chairman and chief executive officer, remarked, "The
combination of solid revenue growth and expense management led to
non-GAAP operating income and EPS that were above our guidance for the
quarter. Having a unique combination of best-of-breed solutions and the
industry's broadest integrated clinical research suite, we are focused
on capitalizing on our market leadership position to drive revenue
growth and margin expansion."
Weiler added, "During the third quarter, a pharmaceutical company in the
top 40 in sales selected Phase Forward's InForm EDC solution for a
multi-year, multi-million dollar commitment, while a leading provider of
information technology, consulting, and business process outsourcing
services selected InForm as part of their outsourcing services to a top
10 pharma. We believe we were chosen due to our unique ability to
effectively and efficiently manage the largest and most complex global
trial environments. In addition, Phase Forward's leadership position
with CROs was further reinforced during the third quarter, as evidenced
by several multi-million dollar commitments. We are encouraged by the
interest levels and cross-sale activity related to our end-to-end suite
of solutions."
For the third quarter of 2009, GAAP income from operations was $2.4
million, compared to $4.4 million in the third quarter of 2008. GAAP net
income for the period was $1.8 million, or $0.04 per diluted share,
compared to $0.08 per diluted share in the third quarter of 2008.
For the third quarter of 2009, non-GAAP revenues were $53.9 million,
which excludes an $802,000 purchase accounting adjustment to record
assumed acquisition deferred revenues and backlog at fair value.
Non-GAAP income from operations was $7.1 million, above the company's
guidance of $5.5 to $6.2 million and compared to $7.4 million in the
prior year period. Non-GAAP net income for the period was $4.8 million,
or $0.11 per diluted share, compared to $5.4 million, or $0.12 per
diluted share, in the third quarter of 2008.
The attached table presents a reconciliation of GAAP to non-GAAP
revenues, income from operations and net income and net income per share
applicable to common stockholders for the three and nine months ended
September 30, 2008 and 2009. Non-GAAP results exclude the impact of
stock-based compensation expense, amortization of intangible assets
associated with certain acquisitions, the purchase accounting adjustment
to record assumed acquisition deferred revenues and backlog at fair
value and restructuring expenses.
Total cash, cash equivalents and investments were $147.2 million at the
end of the third quarter, which was down from $168.7 million at the end
of the prior quarter due primarily to approximately $21.0 million used
in the previously announced acquisitions of Maaguzi and Covance's IRT
business unit. Total deferred revenues were $103.6 million at the end of
the quarter, compared to $91.1 million at the end of the prior quarter
and $86.5 million at the end of the third quarter of 2008.
Third Quarter and Recent Business Highlights
Allergan, Inc., a pharmaceutical company ranking in the top 40 for
worldwide sales, chose Phase Forward to be their EDC supplier by
signing a multi-year, multi-million dollar commitment. Allergan is a
multi-specialty health care company that discovers, develops and
commercializes innovative pharmaceuticals, biologics and medical
devices.
The company signed combined InForm/Clarix IRT agreements with
customers such as LungRX and OncoGenex during the third quarter.
The company's CRO-related non-GAAP revenues of $12.3 million grew 44%
year-over-year during the third quarter. During this period, the
company signed a number of sizeable commitment agreements with CROs,
including Covance, INC Research, Parexel, PharmaNet and SGS.
The company signed a multi-million dollar agreement with the
Department of Defense related to the Army's Pharmacovigilance Center
project, in addition to agreements, totaling over seven figures, with
the FDA relating to extended use of the company's Empirica Signal,
Empirica Study and WebSDM solutions.
Financial Outlook
The following statements are based on current expectations and the
company assumes no obligation to update or confirm them. These
statements are forward-looking and inherently uncertain. Actual results
may differ materially as a result of the factors identified below and
the factors identified in our public filings made with the Securities
and Exchange Commission, or other factors.
For the fourth quarter of 2009, the company expects non-GAAP revenues to
be between $58.0 and $59.5 million. The company expects non-GAAP
operating income to be between $8.2 and $8.9 million. Non-GAAP EPS is
expected to be between $0.12 and $0.13. GAAP EPS is expected to be
between $0.05 and $0.06, including the purchase accounting adjustments
related to some of our acquisitions to record the assumed deferred
revenues and backlog at fair value, non-cash expenses associated with
stock-based compensation expense and the amortization of intangible
assets. The expected EPS reflects an estimated tax rate of approximately
37%.
For the full year 2009, the company expects non-GAAP revenues to be
between $215.0 and $216.5 million. On a non-GAAP basis, operating income
is expected to be between $33.0 and $33.7 million, with non-GAAP EPS
guidance to be between $0.50 and $0.51. GAAP EPS is expected to be
between $0.23 and $0.24, including purchase accounting adjustments
related to some of our acquisitions to record the assumed deferred
revenues and backlog at fair value, non-cash expenses associated with
stock-based compensation expense, the amortization of intangible assets
and restructuring expenses. The expected full year EPS reflects an
estimated tax rate of approximately 37%.
Conference Call
The company plans to host its investor conference call today at 5:00
p.m. ET to discuss its financial results for the third quarter 2009 and
its outlook for the fourth quarter and full year 2009. The investor
conference call will be available via live webcast on Phase Forward's
web site at www.phaseforward.com
under the tab "Investors." To participate by telephone, the domestic
dial-in number is 888-713-4217 and the international dial-in is
1-617-213-4869. The access code is 86750827. Investors are advised to
dial into the call at least ten minutes prior to the call to register.
The webcast will be available for replay until Sunday, November 29, 2009
on the "Investors" page of Phase Forward's website.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. Phase Forward's products
and services have been utilized in over 10,000 clinical trials involving
more than 1,000,000 clinical trial study participants at over 300
organizations and regulatory agencies worldwide including: AstraZeneca,
Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S.
Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research
Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International,
Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare
Products Regulatory Agency. Additional information about Phase Forward
is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based on
historical information are forward-looking statements which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to, among other things,
Phase Forward's expectations and assumptions concerning management's
forecast of financial performance, the performance of Phase Forward's
products and services, future business and operations plans of Phase
Forward's customers, the ability of Phase Forward's customers to realize
benefits from the use of Phase Forward's products and services, planned
acquisitions, integration of acquired businesses, and management's
plans, objectives and strategies. These statements are neither promises
nor guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond Phase Forward's control, which could cause
actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties
include, among other things, changes in our customers' industries; our
ability to convince prospective customers to adopt our solutions;
competition and changes in competition during future periods; changing
customer requirements; governmental regulation; our ability to maintain
profitability; fluctuations in our operating results; long sales and
implementation cycles; our dependence on a limited number of customers
or suppliers; product performance; third party service interruptions or
delays; technology failures; our ability to maintain customer
relationships and contracts; our ability to retain and hire skilled
personnel; our ability to protect our intellectual property rights;
product liability or intellectual property infringement claims brought
against us; acquisitions; our ability to manage our rapid growth; our
ability to obtain capital when desired on favorable terms; and the
volatility of the market price of our common stock. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Phase Forward undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise. For additional
disclosure regarding these and other risks faced by Phase Forward, see
the disclosure contained in Phase Forward's public filings with the
Securities and Exchange Commission including, without limitation, its
most recent Annual Report on Form 10-K.
Non-GAAP Financial Information
Phase Forward provides non-GAAP revenues, income from operations, net
income, and net income per share applicable to common stockholders data
as additional information for its operating results. These measures are
not in accordance with, or an alternative for, generally accepted
accounting principles and may be different from non-GAAP measures used
by other companies. Phase Forward's management believes these non-GAAP
measures are useful to investors because this supplemental information
facilitates comparisons to prior periods. Management uses these non-GAAP
measures to evaluate its financial results, develop budgets and manage
expenditures. Investors are encouraged to review the reconciliations of
these non-GAAP financial measures to the comparable GAAP results, which
are attached to this press release.
Phase Forward Incorporated
Condensed Consolidated Statements of Income
(unaudited)
(in thousands, except per share amounts)
Three Months Ended September 30, Nine Months Ended September 30,
2008 2009 2008 2009
Revenues:
License $ 12,974 $ 15,159 $ 38,675 $ 43,970
Service 30,017 37,960 83,187 110,466
Total revenues 42,991 53,119 121,862 154,436
Costs of revenues:
License(2) 838 559 2,119 1,910
Service(1), (2) 17,686 23,076 50,405 64,220
Total cost of revenues 18,524 23,635 52,524 66,130
Gross margin:
License 12,136 14,600 36,556 42,060
Service 12,331 14,884 32,782 46,246
Total gross margin 24,467 29,484 69,338 88,306
Operating expenses:
Sales and marketing(1), (2) 7,024 8,678 19,958 24,100
Research and development(1) 6,424 9,639 18,003 27,244
General and administrative(1), (2) 6,629 8,796 18,374 26,315
Total operating expenses 20,077 27,113 56,335 77,659
Income from operations 4,390 2,371 13,003 10,647
Other income:
Interest income 1,483 331 4,770 1,473
Other, net (478 ) 120 (229 ) 585
Total other income 1,005 451 4,541 2,058
Income before provision for income taxes 5,395 2,822 17,544 12,705
Provision for income taxes 1,954 1,013 6,407 4,591
Net income $ 3,441 $ 1,809 $ 11,137 $ 8,114
Net income per share applicable to common stockholders:
Basic $ 0.08 $ 0.04 $ 0.27 $ 0.19
Diluted $ 0.08 $ 0.04 $ 0.25 $ 0.18
Weighted average number of common shares used in net
income per share calculations:
Basic 42,194 42,853 42,020 42,637
Diluted 44,065 44,517 43,879 44,338
(1) Amounts include stock-based compensation expense, as follows:
Costs of service revenues $ 437 $ 317 $ 1,278 $ 1,282
Sales and marketing 393 426 1,075 1,303
Research and development 329 1,139 931 2,465
General and administrative 1,133 1,114 2,746 4,140
Total stock-based compensation expense $ 2,292 $ 2,996 $ 6,030 $ 9,190
(2) Amounts include amortization of intangible assets, as follows:
Costs of license revenues $ 327 $ 208 $ 637 $ 557
Costs of service revenues - 282 - 804
Sales and marketing 231 421 431 1,095
General and administrative 7 26 7 78
Total amortization of intangible assets $ 565 $ 937 $ 1,075 $ 2,534
-------------------------------------------------------------------------------
Phase Forward Incorporated
Reconciliation of GAAP Revenues, GAAP Income From Operations and GAAP Net Income to
Non-GAAP Revenues, Non-GAAP Income From Operations and Non-GAAP Net Income
(unaudited)
(in thousands, except per share amounts)
Three Months Ended September 30, Nine Months Ended September 30,
2008 2009 2008 2009
TOTAL REVENUES:
GAAP total revenues $ 42,991 $ 53,119 $ 121,862 $ 154,436
Deferred revenues and backlog adjustments related to acquisitions (1) 201 802 201 2,398
Non-GAAP total revenues $ 43,192 $ 53,921 $ 122,063 $ 156,834
INCOME FROM OPERATIONS:
GAAP income from operations $ 4,390 $ 2,371 $ 13,003 $ 10,647
Stock-based compensation expense 2,292 2,996 6,030 9,190
Amortization of intangible assets 565 937 1,075 2,534
Deferred revenues and backlog adjustments related to acquisitions (1) 201 802 201 2,398
Restructuring - - - 86
Non-GAAP income from operations $ 7,448 $ 7,106 $ 20,309 $ 24,855
NET INCOME:
GAAP net income $ 3,441 $ 1,809 $ 11,137 $ 8,114
Stock-based compensation expense, net of tax 1,462 1,921 3,829 5,869
Amortization of intangible assets, net of tax 360 601 682 1,618
Deferred revenues and backlog adjustments related acquisitions, net of tax (1) 128 514 127 1,531
Restructuring, net of tax - - - 55
Non-GAAP net income $ 5,391 $ 4,845 $ 15,775 $ 17,187
GAAP net income per share applicable to common stockholders:
Diluted $ 0.08 $ 0.04 $ 0.25 $ 0.18
Non-GAAP net income per share applicable to common stockholders:
Diluted $ 0.12 $ 0.11 $ 0.36 $ 0.39
-------------------------------------------------------------------------------
(1) Fair value adjustments to deferred revenues and backlog. Purchase
accounting requires that deferred revenue assumed in an acquisition be
recorded and subsequently recognized at its fair value as of the time of
the acquisition. Consequently, we do not recognize the full amount of
these deferred revenues and backlog. We add back non-GAAP revenues
associated with deferred revenues and backlog that were excluded as a
result of purchase accounting adjustments, as we believe that this
provides information about the operating impact of the acquired business
in a manner consistent with the revenue recognition for our pre-existing
products and services.
Phase Forward Incorporated
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except per share amounts)
As of December 31, As of September 30,
2008 2009
Assets
Current assets:
Cash and cash equivalents $ 131,550 $ 53,011
Restricted cash, current portion 500 -
Short-term investments 27,893 59,490
Accounts receivable, net of allowance of $578 and $856, respectively 39,999 60,366
Acquired future billings, current portion 1,129 516
Deferred set up costs, current portion 2,393 3,142
Prepaid commissions and royalties, current portion 4,524 5,613
Prepaid expenses and other current assets 4,773 6,429
Deferred income taxes, current portion 12,895 12,973
Securities settlement agreement - 4,838
Total current assets 225,656 206,378
Acquired future billings, net of current portion 962 415
Property and equipment, net 36,615 43,829
Deferred set up costs, net of current portion 1,630 2,039
Prepaid commissions and royalties, net of current portion 4,277 5,786
Intangible assets, net of accumulated amortization of $3,624 and $6,157 respectively 27,586 45,118
Goodwill 39,125 59,441
Deferred income taxes, net of current portion 7,107 1,693
Restricted cash, net of current portion 962 962
Long-term investments 18,022 34,725
Securities settlement agreement 5,322 -
Other assets 626 879
Total assets $ 367,890 $ 401,265
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 8,895 $ 7,047
Accrued expenses 22,686 23,969
Leasehold incentive obligation, current portion 791 791
Deferred revenues, current portion 79,918 92,469
Total current liabilities 112,290 124,276
Deferred rent, net of current portion 564 1,741
Leasehold incentive obligation, net of current portion 7,248 6,655
Deferred revenues, net of current portion 8,600 11,177
Other long-term liabilities 1,515 1,614
Total liabilities 130,217 145,463
Stockholders' equity:
Preferred stock, $0.01 par value:
Authorized-----5,000 shares
Issued-----0 shares - -
Common stock, $0.01 par value:
Authorized-----100,000 shares
Issued----- 42,986 and 43,330 shares, respectively 430 433
Additional paid-in capital 283,676 292,849
Treasury stock, 37 shares at cost (111 ) (111 )
Accumulated other comprehensive (loss) income (672 ) 167
Accumulated deficit (45,650 ) (37,536 )
Total stockholders' equity 237,673 255,802
Total liabilities and stockholders' equity $ 367,890 $ 401,265
-------------------------------------------------------------------------------
Phase Forward Incorporated
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
Nine Months Ended September 30,
2008 2009
Operating activities
Net income $ 11,137 $ 8,114
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 7,149 12,088
Stock-based compensation expense 6,030 9,190
Loss on disposal of fixed assets 303 54
Amortization of leasehold incentive obligation - (593 )
Provision for allowance for doubtful accounts 55 386
Deferred income taxes 5,739 2,915
Amortization of discounts or premiums on investments (178 ) (178 )
Change in fair value of short-term investments - (1,005 )
Change in fair value of securities settlement agreement - 484
Changes in assets and liabilities:
Accounts receivable and acquired future billings (502 ) (18,157 )
Deferred costs (1,524 ) (3,453 )
Prepaid expenses and other current assets 864 (1,395 )
Accounts payable 3,843 (2,141 )
Accrued expenses 840 (584 )
Deferred revenue 17,336 11,304
Deferred rent (386 ) 1,177
Net cash provided by operating activities 50,706 18,206
Investing activities
(Increase) decrease in restricted cash (1,462 ) 500
Proceeds from maturities of short-term and long-term investments 50,325 39,428
Purchase of short-term and long-term investments (45,901 ) (86,545 )
Purchase of property and equipment (11,108 ) (16,353 )
Cash paid for acquisitions, net of cash acquired (40,869 ) (34,628 )
Net cash used in investing activities (49,015 ) (97,598 )
Financing activities
Proceeds from issuance of common stock 1,795 1,860
Withholding taxes in connection with vesting of restricted stock (1,247 ) (1,854 )
Net cash provided by financing activities 548 6
Effect of exchange rate changes on cash and cash equivalents (1,239 ) 847
Net increase (decrease) in cash and cash equivalents 1,000 (78,539 )
Cash and cash equivalents at beginning of period 133,401 131,550
Cash and cash equivalents at end of period 134,401 53,011
Short-term and long-term investments at end of period 43,719 94,215
Total cash, cash equivalents and short-term and long-term investments at end of period $ 178,120 $ 147,226
-------------------------------------------------------------------------------
A service of YellowBrix, Inc.
